Compugen (NASDAQ:CGEN) Issues Earnings Results

Compugen (NASDAQ:CGEN) announced its quarterly earnings results on Monday. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01), FiscalAI reports. Compugen had a return on equity of 55.68% and a net margin of 48.57%.The business had revenue of $2.18 million for the quarter, compared to analyst estimates of $1.57 million.

Here are the key takeaways from Compugen’s conference call:

• Compugen said its MAIA-ovarian trial for COM701 is now enrolling at sites in the U.S., Israel, and France, and management said it remains on track to report interim median PFS data in Q1 2027.
• Management reiterated that COM701’s differentiated PVRIG biology may support activity in ovarian cancer, including in patients who are PD-L1 positive or negative, and noted the trial is not stratified by PD-L1 status.
• Compugen highlighted continued external validation of its partnered asset rilvegostomig, citing AstraZeneca’s AACR presentations and ongoing advancement across 11 phase III trials as supportive of the program’s potential.
• The company said its Gilead-partnered GS-0321 phase I dose-escalation study is progressing as planned, with Compugen having already received $90 million and eligible for up to $758 million more in milestones plus royalties.
• Compugen ended the quarter with about $134.9 million in cash and said its runway should fund operations into 2029, allowing continued investment in MAIA-ovarian, GS-0321, and its early-stage pipeline.

Compugen Stock Up 4.0%

Shares of Compugen stock opened at $2.86 on Tuesday. The stock’s fifty day moving average is $2.51 and its 200-day moving average is $2.00. The firm has a market capitalization of $270.41 million, a PE ratio of 7.73 and a beta of 2.79. Compugen has a 12-month low of $1.29 and a 12-month high of $3.23.

Analyst Ratings Changes

A number of analysts have recently commented on CGEN shares. Wall Street Zen raised Compugen from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Lake Street Capital started coverage on Compugen in a research note on Tuesday, April 7th. They issued a “buy” rating and a $6.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a research note on Monday, April 20th. Finally, Truist Financial raised Compugen to a “strong-buy” rating in a research note on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Compugen currently has an average rating of “Moderate Buy” and a consensus price target of $5.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Security National Bank of Sioux City Iowa IA purchased a new position in shares of Compugen during the fourth quarter valued at $38,000. Franklin Resources Inc. purchased a new position in shares of Compugen during the second quarter valued at $56,000. Osaic Holdings Inc. grew its holdings in shares of Compugen by 346.0% during the second quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 34,045 shares in the last quarter. WINTON GROUP Ltd purchased a new position in shares of Compugen during the fourth quarter valued at $84,000. Finally, XTX Topco Ltd purchased a new position in shares of Compugen during the fourth quarter valued at $104,000. Hedge funds and other institutional investors own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.